Floatz logo

Cipralex

Gallbladder Cancer

Massachusetts General HospitalPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the Gallbladder Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Lisata Therapeutics, Inc.
Phase 2BBB
Eloxatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 3BB
Docetaxel
Merck Sharp & Dohme LLC
Phase 2BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

Cipralex is also rated in:

Anxiety DisordersDormant
A
Indicative ·
81 / 100
View asset →
bipolar I disorderDormant
BBB
Indicative ·
77 / 100
View asset →
dysthymic disorderDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →